Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Why It Matters

Employer‑driven coverage could unlock a sizable, untapped market for GLP‑1 therapies, accelerating Lilly’s top‑line growth, while a successful oral GLP‑1 expands its product portfolio beyond injectables.

Key Takeaways

• Employer Connect offers Zepbound at $449 discounted price
• Half of employees lack obesity drug coverage
• Orforglipron reduced A1C more than oral semaglutide
• Potential sales boost expected after 2027 adoption
• Lilly’s growth forecast 25% for 2026

Pulse Analysis

The employer coverage gap represents a hidden revenue stream for weight‑loss drugs, with surveys showing only 20% of mid‑size firms and 43% of large enterprises currently covering GLP‑1 therapies. By bundling Zepbound into a low‑cost, employer‑managed benefit, Lilly sidesteps pharmacy benefit managers and creates a direct channel to millions of workers who would otherwise pay out‑of‑pocket. This model not only expands the addressable market but also builds long‑term relationships with corporate health programs, a trend gaining traction across the pharmaceutical industry.

Orforglipron’s recent trial results signal a potential shift in the oral diabetes and obesity space. Delivering a 2.2% A1C drop and 9.2% weight loss—both superior to Novo’s oral semaglutide—demonstrates that Lilly can compete on efficacy while offering the convenience of a pill. The oral market, though smaller than injectable GLP‑1 sales, is projected to grow as patients and payers seek less invasive options. Successful commercialization could allow Lilly to leverage its existing GLP‑1 brand equity and capture a share of the $3‑4 billion oral diabetes segment, with spill‑over into the larger obesity market.

Together, these initiatives bolster Lilly’s earnings outlook and reinforce its defensive positioning in a competitive therapeutic class. The Employer Connect program may not reflect in earnings until the 2027 fiscal year, but analysts already price in a meaningful upside, reflected in a 24.8% upside target and a 97th‑percentile MarketRank™ score. Coupled with a robust pipeline and a strong dividend, Lilly’s strategy exemplifies how pharma firms can blend innovative access models with pipeline differentiation to sustain growth in a maturing market.